GC Pharma is hoping to commercialize virus treatment

Home > Business > Industry

print dictionary print

GC Pharma is hoping to commercialize virus treatment

GC Pharma is hoping to commercialize its coronavirus treatment under development by the second half of this year, the company said Thursday.

GC5131A is a hyperimmune globulin that is made with immune proteins collected from recovered Covid-19 patients, and GC Pharma said it can expedite development and testing for the treatment candidate as it used the same technology for the coronavirus treatment in making other commercialized drugs on the market.

GC Pharma said its blood plasma-based treatment is competing in terms of development against foreign pharmaceutical companies like Takeda and Grifols, both of which are targeting to launch their Covid-19 treatments this year.

BY KO JUN-TAE [ko.juntae@joongang.co.kr]
Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)